Damiano Fantini

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 3

Top Topics

Drug Administration

Metabolic Syndrome

Long Noncoding Rna

Top Venues

Science advances

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Ekta Patel, Natalia V Malkova, David Crowe, Magali Pederzoli-Ribeil, Damiano Fantini, Manoussa Fanny, Hanumantha Rao Madala, Kurt A Jenkins, Oleg Yerov, Justin M Greene, Wilson Guzman, Caitlin O'Toole, Jacob Taylor, Rebekah K O'Donnell, Parker Johnson, Bernard B Lanter, Brian Ames, Jia Chen, Sallyann Vu, Hsin-Jung Wu, Susan Cantin, Megan McLaughlin, Yu-Shan S Hsiao, Dheeraj S Tomar, Raphael Rozenfeld, Lakshmanan Thiruneelakantapillai, Ronan C O'Hagan, Benjamin Nicholson, Jennifer O'Neil, Carl Uli Bialucha
XTX301, a tumor-activated Interleukin-12 has the potential to widen the therapeutic index of IL-12 treatment for solid tumors as evidenced by pre-clinical studies. Molecular cancer therapeutics (2023)
Haley E Titus, Huan Xu, Andrew P Robinson, Priyam A Patel, Yanan Chen, Damiano Fantini, Valerie Eaton, Molly Karl, Eric D Garrison, Indigo V L Rose, Ming Yi Chiang, Joseph R Podojil, Roumen Balabanov, Shane A Liddelow, Robert H Miller, Brian Popko, Stephen D Miller
Repurposing the cardiac glycoside digoxin to stimulate myelin regeneration in chemically-induced and immune-mediated mouse models of multiple sclerosis. Glia 70 (10) (2022)
Andrea Piunti, Khyati Meghani, Yanni Yu, A Gordon Robertson, Joseph R Podojil, Kimberly A McLaughlin, Zonghao You, Damiano Fantini, MingYi Chiang, Yi Luo, Lu Wang, Nathan Heyen, Jun Qian, Stephen D Miller, Ali Shilatifard, Joshua J Meeks
Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma. Science advances 8 (40) (2022)